S. Vincent Rajkumar MD, FRCPC

Dr. S. Vincent Rajkumar is Editor in Chief of Blood Cancer Journal, and the Edward W. and Betty Knight Scripps Professor of Medicine at the Mayo Clinic, Rochester, Minnesota. He is internationally recognized as a leading expert in the field of multiple myeloma and related plasma cell disorders. His career was profiled in the Lancet in 2011.

Dr. Rajkumar is Chair of the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee. Dr. Rajkumar has a multi-faceted research program in the field of plasma cell disorders involving clinical trials, epidemiologic studies, and laboratory research. He has led numerous phase I, II, and III clinical trials investigating the role of new agents in myeloma, including the pivotal trial that led to the approval of thalidomide in myeloma in the United States. As chair of the ECOG myeloma committee, he leads the design and implementation of several national phase III randomized trials for the disease.

Dr. Rajkumar also leads several large epidemiological studies investigating epidemiology, racial disparities, familial predisposition, prevalence, and progression of various monoclonal gammopathies including monoclonal gammopathy of undetermined significance (MGUS), and multiple myeloma. His current laboratory research is focused on investigating novel agents in myeloma and studying biomarkers for various plasma cell disorders. His research is primarily funded by the US National Institutes of Health. He has published more than 350 peer-reviewed papers primarily in the field of myeloma and related plasma cell disorders, and is the author of over 100 book chapters related to the disease.

Dr. Rajkumar also serves as Associate Editor for the Mayo Clinic Proceedings; Section Editor for multiple myeloma and related disorders for the journal Leukemia; and Associate Editor for the European Journal of Haematology. He is the recipient of the Robert A. Kyle Lifetime Achievement Award (2016), and the Giants of Cancer Care Award (2019).